The MaMTH system, developed by the Stagljar Lab
The March 23rd issue of Nature Methods highlights the Stagljar Lab‘s development of the mammalian membrane two-hybrid (MaMTH) assay and its application to the human epidermal growth receptor (EGFR), mutations of which are associated with lung cancer. Using this approach, they identified CrkII as an interactor of the mutated EGFR and showed that Crk II regulates the stability of mutated EGFR and thus promotes signaling within cancer cells.
“This technology gives us a new tool to examine membrane proteins in their natural environment of the human cell”
– Igor Stagljar
Read the whole publication “The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells” on Nature Methods.
Read the article on the University of Toronto News site by Jim Oldfield that highlights the publication: “New technology sheds light on protein interactions, better lung cancer therapy”
